Midazolam versus fentanyl/droperidol and placebo as intramuscular premedicant.
Midazolam, a new short-acting benzodiazepine with promising premedicant effects, was investigated in a double-blind, randomized clinical trial in 203 patients versus fentanyl/droperidol and placebo. Subjective effects, side-effects, amnesia and overall satisfaction were recorded. Midazolam caused the greatest decrease in anxiety level, and while causing more confusion and somnolence than placebo, caused less confusion and somnolence than fentanyl/droperidol. Half the patients who received midazolam reported anterograde amnesia. No serious side-effects were reported. Patient satisfaction was greater in the midazolam group than in the other groups.
van Wijhe
M
M
de Voogt-Frenkel
E
E
Stijnen
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety / Q000517:prevention & control; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004329:Droperidol / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008874:Midazolam; D008875:Middle Aged; D011229:Preanesthetic Medication
D004338:Drug Combinations; D001569:Benzodiazepines; D004329:Droperidol; D008874:Midazolam; D005283:Fentanyl